Novel Methods to Selectively Eliminate Tumor Infiltrating Regulatory T-Lymphocytes

Request Number N235260
Need details

Pfizer, through its biotechnology unit Rinat, is developing immunotherapeutics for the treatment of cancers.


Pfizer seeks novel targets and methods that allow for selective elimination of tumor infiltrating lymphocytes (TILs), specifically regulatory T-cells (T-reg), in distinct tumor microenvironments (e.g., melanoma versus lung cancer).


Key Success Criteria:

    • Targets and methods with evidence of selective and quantitative depletion of T-reg populations in human tumors
    • Intermediate proof-of-principle approaches, demonstrated in a relevant surrogate mode, may also be considered



Rinat is an independent biotechnology unit within Pfizer’s Worldwide R&D organization. Rinat leads Pfizer’s R&D efforts in Cancer Immunotherapy and is focused on partnering clinical stage oncology and immunology opportunities, with an emphasis on antibody-based therapies that are immunomodulatory, including those that directly engage or impact T-cell function.


Possible Approaches:

    • Both monotherapy and combination approaches using small molecule and/or biologic therapeutics will be considered.
    • Antibody-based approaches could include native antibody directed immunotherapy or antibody drug conjugate approaches. Unique antibody scaffolds and antibodies will also be considered with appropriate in vivo validation of their utility.


Approaches Not of Interest:

Viral, vaccine, and/or cell-based methods are currently not of interest.


Preferred Collaboration Type:

As an independent biotechnology unit within Pfizer, Rinat maintains the unique culture and scientific environment of a small company while exploiting the world-class capabilities and resources of the broader Pfizer R&D organization. Rinat's unique culture allows us to adopt collaborative models that best suit your partnering opportunity. We are confident that you will find Rinat to be a great partner in advancing your science.


How to Respond:

We are looking for a completed Response Template, which may contain a concise abstract/executive summary. The proposal should briefly describe the technical approach and provide information on technology performance, background and description of the responding team and their related experience. To Respond, please use the red Respond Now button located to the right. Please note that only non-confidential information can be accepted.


By submitting a response you represent that the response does not contain and will not be deemed to contain any confidential information of any kind whatsoever. All Personal Information disclosed to Pfizer within a response will be utilized in accord with principles and polices as described at By submitting a response, you also acknowledge and confirm that you have consulted with your Technology Transfer Office, Business Development Office or any other required group and that you have their approval to submit the response. By submitting a response, you acknowledge that the Need's sponsoring organization, in its sole discretion, may select or reject a response or any portion thereof.


Your NineSights community profile should contain all required information in order to provide us with appropriate contact information for your responses. For questions about NineSights privacy and security, please feel free to post in our forums.

Migrated from previous NineSights Community Site
Key Success Criteria
Migrated from previous NineSights Community Site
Preferred Collaboration types
  • To Be Negotiated
Point of Contact
Jonathan Tzeng
Area of Interest
  • Chemical Manufacturing
  • Environmental Services
  • Family & Consumer Products & Services
  • Food & Beverage
  • Medical Products & Services
  • Other
Due Date
April 11, 2014
Award Amount
This page does not have file attachments.
This page does not have file attachments.